Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigenics Acquires Dutch Oncology Target Company Semaia

NEW YORK, April 29 - Hybrigenics has acquired Dutch oncology target discovery company Semania, the companies said today.

 

The acquisition, in which Hybrigenics purchased 100 percent of Semaia's shares, enables Hybrigenics access to Semaia's oncology targets. These include therapeutic targets, both enzymes and cell surface proteins, in the Wnt pathway of colorectal cancer, and in the Ras-Raf and PKB/AKT pathways in other cancers.

 

Hybrigenics, of Paris, will use its yeast-two hybrid proteomics technology to explore the function of Semaia's targets and identify proteins that interact with these targets, the company said.

The company also said it expects the acquisition to "reinforce the international collaborations" it has with research institutes. Semaia, of Utrecht, was co-founded by Professors Hans Bos and Hans Clevers of the University of Utrecht. 

 

In the acquisition, Semiaia CEO Rian De Jonge will become Hybrigenics' executive vice president of R&D, and Bos and Clevers will join Hybrigenics' scientific advisory board.

 

Hybrigenics currently has drug discovery programs in cancer and in infectious diseases including HIV and Hepatitis C.

 

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.